The administration of subcutaneous insulin increases LPL activity and subsequently very low density lipoproteins (VLDL) turnover, resulting in the so called “supernormal” lipid profile seen in T1D patients [18]. The gene discussed is LPL; the disease is type 1 diabetes mellitus.